| Literature DB >> 31898496 |
Louis Bernard1, René Ecochard2,3,4, François Gueyffier5, Laurent Letrilliart6,7.
Abstract
BACKGROUND: Care goals are often implicit, although their identification is a key element of any prescription process. This study aimed to describe the clinical goals of drug prescriptions in general practice, their determinants and the agreement between physicians and patients.Entities:
Keywords: Drug prescription; General practice; Goals; Observational study; Primary care
Mesh:
Year: 2020 PMID: 31898496 PMCID: PMC6941394 DOI: 10.1186/s12913-019-4870-y
Source DB: PubMed Journal: BMC Health Serv Res ISSN: 1472-6963 Impact factor: 2.655
Patients’ and physicians’ characteristics
| Patients | ||
| Age | ||
| ≤ 14 | 372 | (17.4) |
| 15–44 | 616 | (28.8) |
| 45–74 | 840 | (39.2) |
| 75–97 | 313 | (14.6) |
| Gender | ||
| Males | 923 | (43.1) |
| Females | 1218 | (56.9) |
| Patient known by physician | ||
| Yes | 2017 | (94.2) |
| No | 124 | (5.8) |
| Medical fee exemption status | ||
| For long-term condition | 410 | (19.1) |
| For low income | 96 | (4.5) |
| Physicians | ||
| Gender | ||
| Males | 16 | (69.6) |
| Females | 7 | (30.4) |
| Age (yrs) | ||
| 31–39 | 5 | (21.7) |
| 40–49 | 5 | (21.7) |
| 50–59 | 9 | (39.2) |
| 59–66 | 4 | (17.4) |
| Work environment | ||
| Rural | 9 | (39.0) |
| Semi-rural | 8 | (34.8) |
| Urban | 6 | (26.2) |
| Type of practice | ||
| Multidisciplinary group/health care center | 6 | (26.0) |
| Group | 14 | (60.9) |
| Solo | 3 | (13.1) |
Distribution of physicians’ prescription goals according to patients’ characteristics
| Mortality | Morbidity | Cure | Symptom | Quality of life | Functioning | Other or none | Total | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | 429 | (8.5%) | 1128 | (22.4%) | 587 | (11.7%) | 2183 | (43.3%) | 534 | (10.6%) | 91 | (1.8%) | 84 | (1.7%) | 5036 (100%) | |
| Gender | ||||||||||||||||
| Male | 213 | (10.0%) | 564 | (26.4%) | 213 | (10.0%) | 858 | (40.2%) | 217 | (10.2%) | 41 | (1.9%) | 28 | (1.3%) | 2134 (100%) | |
| Female | 216 | (7.4%) | 564 | (19.4%) | 374 | (12.9%) | 1325 | (45.7%) | 317 | (10.9%) | 50 | (1.7%) | 56 | (1.9%) | 2902 (100%) | |
| Age | ||||||||||||||||
| 0–44 | 44 | (2.7%) | 151 | (9.1%) | 271 | (16.4%) | 970 | (58.7%) | 151 | (9.1%) | 24 | (1.5%) | 42 | (2.5%) | 1653(100%) | |
| ≥45 | 385 | (14.7%) | 977 | (31.6%) | 316 | (6.7%) | 1213 | (31.9%) | 383 | (11.7%) | 67 | (2.1%) | 42 | (1.3%) | 3383 (100%) | |
| Patient known by physician | ||||||||||||||||
| Yes | 420 | (8.7%) | 1103 | (23.0%) | 561 | (11.7%) | 2046 | (42.6%) | 512 | (10.7%) | 83 | (1.7%) | 79 | (1.6%) | 4804 (100%) | |
| No | 9 | (3.9%) | 25 | (10.8%) | 26 | (11.2%) | 137 | (59.1%) | 22 | (9.5%) | 8 | (3.4%) | 5 | (2.2%) | 232 (100%) | |
| Long term condition | ||||||||||||||||
| Yes | 285 | (16.6%) | 564 | (32.9%) | 112 | (6.5%) | 492 | (28.7%) | 200 | (11.7%) | 39 | (2.3%) | 21 | (1.2%) | 1713 (100%) | |
| No | 144 | (4.3%) | 564 | (17.0%) | 475 | (14.3%) | 1691 | (50.9%) | 334 | (10.1%) | 52 | (1.6%) | 63 | (1.9%) | 3323 (100%) | |
| Low income | NA | |||||||||||||||
| Yes | 18 | (8.2%) | 29 | (13.2%) | 25 | (11.4%) | 108 | (49.1%) | 36 | (16.4%) | 0 | (0%) | 4 | (1.8%) | 220 (100%) | |
| No | 411 | (8.5%) | 1099 | (22.8%) | 562 | (11.7%) | 2075 | (43.1%) | 498 | (10.3%) | 91 | (1.7%) | 91 | (1.7%) | 4816 (100%) | |
NA Chi-square test not available due to a theoretical sample < 5
The most frequent 4th level ATC sub-classes according to prescription goals
| Goal | ATC sub-class | |
|---|---|---|
Mortality ( | Platelet aggregation inhibitors excl. Heparin (B01AC) | 51 (11.9%) |
| HMG CoA reductase inhibitors (statin) (C10AA) | 48 (11.2%) | |
| Beta blocking agents, selective (C07AB) | 32 (7.5%) | |
| ACE inhibitors, plain (C09AA) | 30 (7.0%) | |
| Angiotensin II antagonists, plain (C09CA) | 22 (5.1%) | |
Morbidity ( | HMG CoA reductase inhibitors (statin) (C10AA) | 106 (9.4%) |
| Vitamin D and analogues (A11CC) | 74 (6.6%) | |
| ACE inhibitors, plain (C09AA) | 65 (5.8%) | |
| Beta blocking agents, selective (C07AB) | 59 (5.2%) | |
| Calcium channel blockers, dihydropyridine derivatives (C08CA) | 54 (4.8%) | |
| Platelet aggregation inhibitors excl. Heparin (B01AC) | 54 (4.8%) | |
Cure ( | Penicillins with extended spectrum (J01CA) | 59 (10.1%) |
| Glucocorticoids (H02AB) | 38 (6.5%) | |
| NSAID propionic acid derivatives (M01AE) | 31 (5.3%) | |
| Selective serotonin reuptake inhibitors (N06AB) | 29 (4.9%) | |
| Imidazole and triazole derivatives for topical use (D01AC) | 25 (4.3%) | |
Symptom ( | Anilidesa (N02BE) | 559 (25.6%) |
| NSAID propionic acid derivatives (M01AE) | 121 (5.5%) | |
| Proton pump inhibitors (A02BC) | 113 (5.2%) | |
| Corticosteroids for nasal use (R01AD) | 105 (4.8%) | |
| Other drugs for functional gastrointestinal disorders (A03AX) | 78 (3.6%) | |
Quality of life ( | Anilidesa (N02BE) | 51 (9.6%) |
| Benzodiazepine derivatives (N05BA) | 32 (6.0%) | |
| Benzodiazepine related drugs (N05CF) | 30 (5.6%) | |
| Selective serotonin reuptake inhibitors (N06AB) | 30 (5.6%) | |
| Proton pump inhibitors (A02BC) | 25 (4.7%) | |
Functioning ( | Other anti-inflammatory and antirheumatic agents, non-steroids (M01AX) | 7 (7.7%) |
| Vitamin D and analogues (A11CC) | 4 (4.4%) | |
| Anilidesa (N02BE) | 4 (4.4%) | |
| Other nasal preparations (R01AX) | 4 (4.4%) | |
Other ( | Progestogens and estrogens, fixed combinations (G03AA) | 9 (15.0%) |
| Progestogens and estrogens, sequential preparations (G03AB) | 6 (10.0%) | |
| Bacterial and viral vaccines, combined (J07CA) | 3 (5.0%) | |
None ( | Vitamin D and analogues (A11CC) | 4 (16.7%) |
| Antiseptics biguanides and amidines (D08AC) | 3 (12.5%) | |
| Natural opium alkaloids (N02AA) | 2 (8.3%) | |
| Anilidesa (N02BE) | 2 (8.3%) | |
| Mucolytics (R05CB) | 2 (8.3%) |
aIncluding paracetamol
Fig. 1Distribution of patients’ and physicians’ prescription goals
Determinants of physician’s choice of a specific goal
| Specific goals | Non-specific goals | Univariate analysis | Multivariable analysisa | |||||
|---|---|---|---|---|---|---|---|---|
| OR | [IC 95%] | OR | [IC95%] | |||||
| Characteristics of the health problem managed | ||||||||
| Psycho-social | 93 | (4.3%) | 323 | (11.5%) | 1.00 | 1,00 | ||
| Somatic | 2051 | (95.7%) | 2485 | (88.5%) | 2.86 | [2.27; 3.57] | 3.23 | [2.56; 4.17] |
| Characteristics of the patient | ||||||||
| Age (yrs) | ||||||||
| < 50 | 554 | (25.8%) | 1285 | (45.8%) | 1.00 | 1.00 | ||
| ≥ 50 | 1590 | (74.2%) | 1523 | (54.2%) | 2.42 | [2.14; 2.73] | 1.12 | [1.09; 1.15] |
| Gender | ||||||||
| Females | 1154 | (53.8%) | 1692 | (60.3%) | 1.00 | 1,00 | ||
| Males | 990 | (46.2%) | 1116 | (39.7%) | 1.30 | [1.16; 1.45] | 1.23 | [1.09; 1.39] |
| Long-term condition | ||||||||
| No | 1183 | (55.2%) | 2077 | (74.0%) | 1.00 | 1,00 | ||
| Yes | 961 | (44.8%) | 731 | (26.0%) | 2.31 | [2.05; 2.60] | 1.70 | [1.47; 1.97] |
| Low income | ||||||||
| Yes | 72 | (3.4%) | 144 | (5.0%) | 1.00 | 1.00 | ||
| No | 2072 | (96.6%) | 2664 | (95.0%) | 1.56 | [1.17; 2.08] | 1.30 | [0.95; 1.79] |
| Patient known by the physician | ||||||||
| No | 60 | (2.8%) | 167 | (5.9%) | 1.00 | 1.00 | ||
| Yes | 2084 | (97.2%) | 2641 | (94.1%) | 2.20 | [1.63; 2.97] | 1.63 | [1.19; 2.23] |
| Characteristics of the physician | ||||||||
| Work environment | ||||||||
| Urban | 539 | (25.1%) | 789 | (28.1%) | 1.00 | 1.00 | ||
| Rural or semi-rural | 1605 | (74.9%) | 2019 | (71.9%) | 1.16 | [1.02; 1.32] | 1.20 | [0.98; 1.47] |
aAdjusted to physician’s age and center